miRNA Tools and Services Market by Product [Research Tools (Kits, Reagents, and Other Consumables) and Services (miRNA Extraction Services, Quantification Services, Microarray Services, Sequencing Services, Functional Studies Services, and Others)], Technology [Extraction Tools, qRT-PCR, NGS, Microarray, Functional Analysis Tools and Others], and End User (Research & Academic Institutes; IVD, Pharma & Biotech Companies; and CROs) - Global Opportunity Analysis and Industry Forecast, 2014-2022miRNA is a set of small, non-coding RNA molecules that regulate gene expression post transcription. These molecules have an impact on a wide range of biological functions such as cell cycle control, stem cell differentiation, immune modulation, viral replication, and metabolic control. As the aforementioned processes are involved in the pathology of various diseases, tests performed on miRNAs help in disease treatment. Moreover, miRNAs can be easily manipulated than proteins, thus making them more useful for clinical diagnostics and therapeutics applications.
The global miRNA tools and services market was valued at $146 million in 2015 and is expected to reach $620 million by 2022, growing at a CAGR of 23.4% during the forecast period. It is expected to witness significant growth owing to the rise in incidence of cancer, auto-immune, and cardiovascular diseases. In addition, miRNA molecules possess specific properties, such as higher tissue and organ specificity; and ability to cross the blood–brain barrier easily, that make them a favorable option to be used as biomarkers for a variety of neurological diseases, thereby driving the market growth. However, quantification challenges and development of in-use techniques, such as microarray, hamper the market growth.
The global miRNA tools and services market is segmented on the basis of product, technique, end user, and geography. The miRNA tools and services market is bifurcated into research tools and services. Research tools market is further divided into reagents, kits, and consumables. On the other hand, the services market is classified into miRNA extraction services, quantification services, microarray services, sequencing services, functional studies services, and others. Based on techniques, the market is segmented into extraction tools, qRT-PCR, NGS, microarray, functional analysis tools (such as miRNA mimetics, inhibitors, and target site blockers), and others (such as labeling, ISH, and northern blotting tools). The end-user market is divided into research & academic institutes; IVD, pharma, and biotech companies; and CROs. The market is analyzed across four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
Prominent players have adopted product development (including product launches and approvals) as their key developmental strategy to expand their product portfolio. For instance, in April 2010, NanoString Technologies, Inc. launched a new assay kit for miRNA analysis, which includes the multiplexed assay for profiling the human miRNA transcriptome in a single tube. This assay kit facilitates in direct digital detection and counting of miRNAs without the use of PCR amplification.
This report provides an extensive analysis of the current trends, emerging estimations, and dynamics in the global miRNA tools and services market from 2014 to 2022.
Comprehensive analysis of all regions is provided to determine the prevailing market opportunities.
It presents a detailed quantitative analysis and estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- and country-wise market conditions are comprehensively analyzed.
miRNA Tools and Services Market Key Segments
miRNA Extraction Services
Functional Studies Services
Functional Analysis Tools
By End User
Research & Academic Institutes
IVD, Pharma, and Biotech Companies
Rest of Europe
Rest of Asia-Pacific
Republic of South Africa
Rest of LAMEA
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2. EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3. MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. TOP PLAYER POSITIONING
3.4. MARKET DYNAMICS
220.127.116.11. Increasing incidence of cancer and cardiovascular disorders
18.104.22.168. Increased research funding for miRNA
22.214.171.124. Development of in-house tools reduces commercial consumption
126.96.36.199. Challenges in quantification of miRNA
188.8.131.52. Application of miRNA technology
184.108.40.206.1. miRNA biomarkers
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4. GLOBAL miRNA TOOLS AND SERVICES MARKET, BY PRODUCTS AND SERVICES
4.1.1. Market size and forecast
4.2. RESEARCH TOOLS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3.1. Market size and forecast
220.127.116.11. miRNA extraction services
18.104.22.168.1. Market size and forecast
22.214.171.124. Quantification services
126.96.36.199.1. Market size and forecast
188.8.131.52. Microarray services
184.108.40.206.1. Market size and forecast
220.127.116.11. Sequencing services
18.104.22.168.1. Market size and forecast
22.214.171.124. Functional studies services
126.96.36.199.1. Market size and forecast
188.8.131.52. Other services
184.108.40.206.1. Market size and forecast
CHAPTER 5. GLOBAL miRNA TOOLS AND SERVICES MARKET, BY TECHNOLOGY
5.1.1. Market size and forecast
5.2.1. Market size and forecast
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. FUNCTIONAL ANALYSIS TOOLS
5.5.1. Market size and forecast
5.6. miRNA EXTRACTION TOOLS
5.6.1. Market size and forecast
5.7.1. Market size and forecast
CHAPTER 6. GLOBAL miRNA TOOLS AND SERVICES MARKET, BY END USER
6.1.1. Market size and forecast
6.2. RESEARCH AND ACADEMIC INSTITUTES
6.2.1. Market size and forecast
6.3. IVD, PHARMA & BIOTECH COMPANIES
6.3.1. Market size and forecast
6.4.1. Market size and forecast
CHAPTER 7. GLOBAL miRNA TOOLS AND SERVICES MARKET, BY REGION
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast
7.3.1. Key market trends
7.3.2. Growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Russia market size and forecast
7.3.10. Rest of Europe market size and forecast
7.4.1. Key market trends
7.4.2. Growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. Australia market size and forecast
7.4.7. India market size and forecast
7.4.8. South Korea market size and forecast
7.4.9. Taiwan market size and forecast
7.4.10. Indonesia market size and forecast
7.4.11. Thailand market size and forecast
7.4.12. Rest of Asia-Pacific market size and forecast
7.5.1. Key market trends
7.5.2. Growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil market size and forecast
7.5.5. Turkey market size and forecast
7.5.6. Venezuela market size and forecast
7.5.7. Saudi Arabia market size and forecast
7.5.8. Republic of South Africa market size and forecast
7.5.9. Colombia market size and forecast
7.5.10. Argentina market size and forecast
7.5.11. Rest of LAMEA market size and forecast
CHAPTER 8. COMPANY PROFILES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments, 2014-2016
8.1.6. Key strategy share, 2014-2016 (%)
8.2. THERMO FISHER SCIENTIFIC INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments, 2014-2016
8.2.6. Key strategy share, 2014-2016 (%)
8.3. ILLUMINA, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments, 2014-2016
8.3.6. Key strategy share, 2014-2016 (%)
8.4. AGILENT TECHNOLOGIES
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments, 2014-2016
8.4.6. Key strategy share, 2014-2016 (%)
8.5. GE HEALTHCARE DHARMACON INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments, 2014-2016
8.5.6. Key strategy share, 2014-2016 (%)
8.6. GENECOPOEIA, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments, 2014-2016
8.6.6. Key strategy share, 2014-2016 (%)
8.7. PROMEGA CORPORATION
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Key strategic moves and developments, 2014-2016
8.7.5. Key strategy share, 2014-2016 (%)
8.8. BIO-RAD LABORATORIES, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments, 2014-2016
8.8.6. Key strategy share, 2014-2016 (%)
8.9. MERCK & CO., INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments, 2014-2016
8.9.6. Key strategy share, 2014-2016 (%)
8.10. NEW ENGLAND BIOLABS
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Key strategic moves and developments, 2014-2016
8.10.5. Key strategy share, 2014-2016 (%)
MicroRNAs(miRNAs) are a class of non-coding RNAs that play a major role in regulating gene expressions. These molecules work at the post-transcription level and modify the expression of around 30% of all mammalian protein-encoding genes. Use of bioinformatics and technologically advanced systems (such as NGS) and rise in incidence of chronic disorders drive the market growth. In addition, the ability of miRNAs to act as diagnostic biomarkers and predictors of drug response are anticipated to drive the demand for miRNA. However, the challenges related to the quantification and the development of in-house miRNA research tools such as microarrays restrict the market growth.
The qRT-PCR technology segment is expected to maintain its dominant position throughout the analysis period due to the increase in incidence of chronic diseases such as cancer and cardiovascular disorders. The rise in demand for the identification of miRNA in different organisms and their associated role as a diagnostic biomarker for the disease also boost the market growth.
Research and academic institutes segment dominated the market with more than two-fifths of the total market in 2015. This is primarily attributed to the increase in research projects undertaken to test the ability of miRNA as candidates of disease biomarkers.
Key Findings of the Study:
Research tools led the global miRNA tools and services market, and accounted for nearly four-fifths of the total market in 2015.
Functional studies services segment is projected to grow at highest CAGR of 31.2% during the forecast period.
CROs is the fastest growing segment and is expected to grow at a CAGR of 27.4% during the forecast period.
qRT-PCR technology segment occupied nearly one-third of the market in 2015.
In 2015 Japan was the major shareholder and accounted for almost one-third of the Asia-Pacific market.
North America led the overall market in 2015 and is expected to maintain its dominance throughout the forecast period. This is attributed to the increased funding for miRNA research and increase in incidence of chronic disorders such as cancer. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period owing to increase in investment by pharma and biotech companies in the emerging markets (such as India and China).
The major companies profiled in the report include QIAGEN (Exiqon), Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, GE Healthcare Dharmacon Inc., GeneCopoeia, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., and New England Biolabs.
- QIAGEN (Exiqon)
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies
- GE Healthcare Dharmacon Inc.
- GeneCopoeia, Inc.
- Promega Corporation
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc.
- New England Biolabs